A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
← catalyst calendarNCT07259213 · readout in 834 d
Sponsored by Radiopharm Theranostics, Ltd (industry) · RADX — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
73estimated
Sites
2
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-05 | actual | When the study began enrolling |
| Primary completion | 2028-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Castration-resistant Prostate Cancer
Intervention
- Drug: 161Tb RAD402
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment emergent adverse events of 161Tb RAD402 (phase 1) (Safety)
measured 6 weeks
Recommended dose(s) of 161Tb RAD402 for future exploration (phase 1)
measured 6 weeks
Preliminary anti-tumor activity, as defined by biochemical response, in participants who are treated with 161Tb RAD402 at the RP2D (phase 2a)
measured Up to 30 weeks
Permalink · RADX's whole pipeline · Catalyst calendar · Every registered study · What changed